Dyne Therapeutics Inc - Asset Resilience Ratio

Latest as of December 2025: 18.30%

Dyne Therapeutics Inc (DYN) has an Asset Resilience Ratio of 18.30% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read debt load of Dyne Therapeutics Inc for a breakdown of total debt and financial obligations.

Liquid Assets

$217.19 Million
Cash + Short-term Investments

Total Assets

$1.19 Billion
All company assets

Resilience Assessment

Good
Financial Resilience Level

Asset Resilience Ratio Trend (2007–2025)

This chart shows how Dyne Therapeutics Inc's Asset Resilience Ratio has changed over time. See Dyne Therapeutics Inc (DYN) net assets for net asset value and shareholders' equity analysis.

Liquid Assets Composition Over Time

This chart breaks down Dyne Therapeutics Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see Dyne Therapeutics Inc (DYN) market capitalisation.

Current Liquid Assets Breakdown

Component Amount % of Total Assets
Cash & Equivalents $0.00 0%
Short-term Investments $217.19 Million 18.3%
Total Liquid Assets $217.19 Million 18.30%

Asset Resilience Insights

  • Good Liquidity Position: Dyne Therapeutics Inc maintains a healthy 18.30% of assets in liquid form.
  • This level provides good financial flexibility while maintaining productive asset deployment.
  • The company has significant short-term investments, indicating active treasury management.

Dyne Therapeutics Inc Industry Peers by Asset Resilience Ratio

Compare Dyne Therapeutics Inc's asset resilience ratio with other companies in the same industry.

Company Industry Asset Resilience Ratio
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
Biotechnology 3.28%
Summit Therapeutics PLC
NASDAQ:SMMT
Biotechnology 0.00%
Argen-X
F:1AE
Biotechnology 25.67%
Zhejiang Ausun Pharmaceutical Co Ltd
SHG:603229
Biotechnology 0.21%
R&G PharmaStudies Co. Ltd. A
SHE:301333
Biotechnology 35.96%
Shouyao Holdings (Beijing) Co. Ltd. A
SHG:688197
Biotechnology 79.48%
Innovita Biological Technology Co. Ltd. A
SHG:688253
Biotechnology 70.49%
Sunmax Biotechnology Co Ltd
TWO:4728
Biotechnology 10.53%

Annual Asset Resilience Ratio for Dyne Therapeutics Inc (2007–2025)

The table below shows the annual Asset Resilience Ratio data for Dyne Therapeutics Inc.

Year Asset Resilience Ratio (%) Liquid Assets Total Assets Change
2025-12-31 18.30% $217.19 Million $1.19 Billion -11.62pp
2024-12-31 29.92% $206.82 Million $691.23 Million +29.03pp
2023-12-31 0.89% $1.47 Million $165.08 Million -26.48pp
2022-12-31 27.38% $83.86 Million $306.32 Million -13.91pp
2021-12-31 41.29% $175.75 Million $425.66 Million +28.70pp
2020-12-31 12.58% $44.46 Million $353.33 Million +12.31pp
2017-12-31 0.27% $32.00 Million $11.77 Billion -0.72pp
2016-12-31 1.00% $130.00 Million $13.05 Billion +0.13pp
2015-12-31 0.87% $100.00 Million $11.54 Billion +0.17pp
2014-12-31 0.69% $78.00 Million $11.23 Billion +0.22pp
2013-12-31 0.47% $25.00 Million $5.29 Billion +0.19pp
2012-12-31 0.29% $13.00 Million $4.54 Billion -1.39pp
2011-12-31 1.67% $69.00 Million $4.13 Billion +0.61pp
2010-12-31 1.06% $106.00 Million $10.01 Billion +0.35pp
2009-12-31 0.71% $78.00 Million $10.95 Billion +0.10pp
2008-12-31 0.61% $87.00 Million $14.21 Billion -0.17pp
2007-12-31 0.79% $104.00 Million $13.22 Billion --
pp = percentage points

About Dyne Therapeutics Inc

NASDAQ:DYN USA Biotechnology
Market Cap
$2.87 Billion
Market Cap Rank
#5076 Global
#1615 in USA
Share Price
$17.39
Change (1 day)
-0.91%
52-Week Range
$8.18 - $24.29
All Time High
$47.04
About

Dyne Therapeutics, Inc., a clinical-stage neuromuscular disease company, focuses on discovering and developing therapeutics for neuromuscular diseases in the United States. The company is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; facioscapulohumeral dystrophy; and Pompe disease, as well as rare skeletal mus… Read more